PTEN and melanoma: These findings indicate that alterations in both MAPK and AKT pathways can be the cause of resistance to vemurafenib and induction of p-AKT in resistant melanoma cell lines is rather a more general phenomenon and not solely limited to PTEN mutant cell lines.